ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight
1 January 2026
1 min read

ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight

NEW YORK, January 1, 2026, 09:22 ET — Market closed

Predictive Discovery Ltd said Robex Resources shareholders voted 94.54% in favour of the companies’ proposed merger, clearing a key condition for the all-share deal, an exchange filing showed. “We are delighted with the strong support shown by Robex shareholders for the Transaction,” CEO and Managing Director Andrew Pardey said, adding the combined group expects production of more than 400,000 ounces of gold a year by 2029. Predictive said the transaction is expected to close in the first quarter of 2026, subject to Québec court approval and regulatory consents, including from the governments of Guinea and Mali. 1

The vote moves the deal closer to completion after months of shifting expectations around one of the ASX’s more active gold situations. Investors now shift focus from shareholder support to execution risk and the timing of remaining sign-offs.

Cross-border mining mergers often hinge on approvals and funding, and all-share structures can keep prices jumpy as investors model dilution and closing risk. That matters because the value of what Robex holders receive will move with Predictive’s share price into completion.

Under the terms, Robex shareholders will receive 7.862 Predictive shares for each Robex share, valuing the deal at about A$2.17 billion ($1.45 billion), Reuters reported. 2

Perseus Mining’s A$2.1 billion bid for Predictive lapsed earlier in December after Robex tabled a superior offer, Reuters reported. 3

An all-share deal means investors are paid in stock rather than cash, so the effective price of the merger moves day by day. Traders who want the deal exposure without taking full market risk often hedge by selling the acquirer’s shares, which can weigh on the stock while approvals are pending.

Deal risk still sits in the driver’s seat. Any change to the expected timetable, or new disclosure around funding and development sequencing, is likely to show up quickly in the price.

Before the next session, Predictive shares last closed down 3.9% at A$0.735 on Dec. 31. The stock has traded between about A$0.63 and A$0.77 in December, leaving near-term support around A$0.70 and resistance near A$0.77. 4

Investors will watch for updates on the remaining approvals and for signals the closing schedule is holding. Any slippage tends to matter more in stock-based deals because the consideration is tied to the buyer’s shares.

Stock Market Today

TSMC stock price jumps as chip rally returns — what to watch before Feb. 10 sales update

7 February 2026
TAIPEI, Feb 7, 2026, 23:19 (GMT+8) — Market closed. Taiwan Semiconductor Manufacturing Co’s U.S.-listed American depositary receipts (TSM) jumped 5.5% on Friday to $348.85, after trading between $330.15 and $350.81. In Taipei, the stock (2330.TW) closed up 0.85% at NT$1,780, its high for the day, with about 35 million shares changing hands. 1 The bounce matters because the AI trade has been wobbling, and money has started to move away from software and back into the hardware that runs large models. Semiconductor stocks are up about 65% since early 2025, while software and services shares are down 8%, a Reuters
Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
BSE share price today: BSE Ltd slips as investors brace for December-quarter results
Previous Story

BSE share price today: BSE Ltd slips as investors brace for December-quarter results

Nvidia stock today: China H200 rush puts TSMC ramp-up and CES in focus as markets shut
Next Story

Nvidia stock today: China H200 rush puts TSMC ramp-up and CES in focus as markets shut

Go toTop